Journal of Drug Metabolism & Toxicology
Open Access
ISSN: 2157-7609
+44-77-2385-9429
ISSN: 2157-7609
+44-77-2385-9429
Dejenie Shiferaw, Abebe Aseffa, Melese Hailu Legese, Tesfaye Legesse, Hiwot Ketema and Kassu Desta
Ethiopian Public Health Institute (EPHI), Ethiopia
Posters & Accepted Abstracts: J Drug Metab Toxicol
The global emergence and spread of Extended-spectrum beta-lactamases (ESBLs) producing Enterobacteriaceae have been threatening the ability to treat infection. Hence, this study aimed to determine the prevalence of ESBLs producing and multi-drug resistance (MDR) Enterobacteriaceae (ESBLs-E) from different clinical specimens in Addis Ababa, Ethiopia. A cross-sectional study was conducted from January 1 to May 30, 2017 at EPHI. Identification and antimicrobial susceptibility testing (on Muller Hinton agar) was performed on 426 Enterobacteriaceae isolates. All Enterobacteriaceae were screened for ESBLs production using cefotaxime and ceftazidime as per CLSI guideline. ESBLs specious Enterobacteriaceae were confirmed by combination disk test (CDT). Data was entered and analyzed by using SPSSV20. The most frequent Enterobacteriaceae were E. coli 228 (53.5%) and K. pneumoniae 103 (24.1 %). The magnitude of ESBLs-E was 246 (57.7%). The highest frequencies of ESBLs-E were observed in blood specimen (84.4%) and the highest ESBLs production was observed in K. pneumoniae (85.4%). Highest resistance level was seen to sulfamethoxazole-trimethoprim (77.0%), augumentin (71.6%), cefotaxime (62.2%), cefepime (60.3) and ceftazidime (60.8%). The resistance to meropenem, amikacin and cefoxitin were 5.2%, 13.8% and 25.1% respectively. The overall magnitude of MDR level was 68.3%. Of ESBLs-E, 96.3% of them were MDR (P<0.001). There was a high prevalence of ESBLs-E and MDR isolate in Addis Ababa. Most of ESBLs-E was isolated primarily in blood and urine. The highest ESBLs production was observed among K. pneumoniae. dejenie21@gmail.com